Welcome to our dedicated page for Revolution Medicines SEC filings (Ticker: RVMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Revolution Medicines, Inc. (RVMD) provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed late-stage clinical oncology company, Revolution Medicines uses these filings to report on its financial condition, clinical and regulatory milestones, and significant corporate agreements related to its RAS(ON) inhibitor pipeline.
Investors reviewing RVMD’s filings will find current reports on Form 8-K that describe material events such as clinical data updates, FDA designations and strategic financings. For example, the company has filed 8-Ks detailing Breakthrough Therapy Designation and a Commissioner’s National Priority Voucher for daraxonrasib, pipeline updates in pancreatic ductal adenocarcinoma and non-small cell lung cancer, and a Royalty Purchase Agreement with Royalty Pharma covering potential future net product sales of daraxonrasib and zoldonrasib.
Other 8-K filings discuss term loan facilities linked to regulatory approvals and sales milestones, leadership changes at the board and executive levels, and the listing of Revolution Medicines’ common stock (RVMD) and warrants (RVMDW) on The Nasdaq Stock Market LLC. Periodic filings such as Forms 10-Q and 10-K, referenced in the company’s forward-looking statements, provide more comprehensive discussions of risk factors, research and development activities, and overall business strategy.
On Stock Titan, these SEC filings are presented with real-time updates from EDGAR and AI-powered summaries that highlight key points, such as how financing agreements relate to daraxonrasib and zoldonrasib, or what new clinical or regulatory information is disclosed. Users can quickly identify items related to quarterly results (10-Q), annual reports (10-K), and current reports (8-K), as well as monitor registered securities like RVMD and RVMDW.
This page helps readers understand how Revolution Medicines reports on its RAS(ON) inhibitor programs, financial position and significant corporate events through its SEC disclosures, with AI tools simplifying navigation of complex oncology and financing information.
Revolution Medicines (RVMD) insider activity: On October 16–17, 2025, President & CEO and director Mark A. Goldsmith exercised 20,000 stock options at $1.12 and sold 20,000 common shares pursuant to a Rule 10b5-1(c) trading plan adopted on December 19, 2024. Sales were 10,000 shares at a weighted average $50.4701 on Oct 16 and 10,000 shares at $55 on Oct 17.
Following these transactions, he directly beneficially owns 452,309 shares, which includes 193,475 restricted stock units. He also reports indirect holdings of 20,424, 20,424, and 465,604 shares held in family trusts. After the option exercises, 26,479 stock options remain beneficially owned.
Revolution Medicines (RVMD) announced an FDA milestone. On October 16, 2025, the U.S. Food and Drug Administration granted the company a non‑transferrable voucher for daraxonrasib, its RAS(ON) multi‑selective inhibitor, under the Commissioner’s National Priority Voucher pilot program.
This update signals regulatory recognition tied to daraxonrasib’s program status. The voucher is non‑transferrable and is associated specifically with the FDA’s pilot initiative. No financial terms or commercial arrangements were disclosed in this notice.
Revolution Medicines (RVMD) reported an insider transaction by an officer on 10/13/2025. The reporting person exercised 25,000 stock options at an exercise price of $4.73 per share, then sold 25,000 shares of common stock at a weighted average price of $48.5416. The trades were made under a Rule 10b5-1 trading plan adopted on February 28, 2025.
Following these transactions, the reporting person beneficially owned 284,047 shares, which includes 84,000 restricted stock units, held directly. The filing also shows 5,055 derivative securities (stock options) remaining beneficially owned. The officer’s title is President, Research and Development.
Jeff Cislini, General Counsel of Revolution Medicines, Inc. (RVMD), reported an insider sale. On 09/24/2025 he disposed of 1,799 shares of common stock at a price of $44.26 per share under a previously adopted 10b5-1 trading plan. After the sale he beneficially owned 50,425 shares in total, which the filing specifies includes 43,910 restricted stock units. The Form 4 was signed on behalf of Mr. Cislini by an attorney-in-fact on 09/26/2025.
Revolution Medicines insider filing details a small, routine proposed sale of company stock. The notice reports that Jeffrey Todd Cislini plans to sell 1,799 common shares through Morgan Stanley Smith Barney on 09/24/2025, with an aggregate market value of $79,524.80 based on the filing. The shares were acquired as restricted stock units on 09/15/2025 and payment or settlement is recorded on that same acquisition date. The filer also disclosed a prior sale of 1,869 shares on 09/16/2025 for gross proceeds of $85,646.74. The filing includes the standard representation that the seller is not aware of undisclosed material information.
Wei Lin, Chief Medical Officer of Revolution Medicines, Inc. (ticker shown in filing as RVMD), reported a sale of 2,160 shares of Common Stock on 09/16/2025 at a price of $45.8249 per share. The filing states the sale was made under a Rule 10b5-1 instruction adopted on December 23, 2024 to satisfy the reporting person’s tax withholding obligation upon the vesting of restricted stock units (RSUs) after March 15, 2025. After the transaction, Wei Lin beneficially owned 88,339 shares, which the filing notes includes 58,850 restricted stock units. The form was signed by an attorney-in-fact on behalf of Wei Lin on 09/18/2025.
Revolution Medicines insider sale to cover RSU taxes — The company's President of Research and Development, Stephen Michael Kelsey, reported a sale of 5,367 shares of common stock at $45.8249 per share executed under a Rule 10b5-1 plan to satisfy tax withholding on restricted stock unit vesting. After the transaction the filing reports beneficial ownership of 284,047 shares, which includes 84,000 RSUs. The sale is described as pursuant to a pre-existing 10b5-1 instruction adopted in May 2023.
Margaret A. Horn, Chief Operating Officer and Director of Revolution Medicines, reported a sale of 4,775 shares of the issuer's common stock on 09/16/2025 at a reported price of $45.8249 per share. After the transaction she beneficially owns 145,900 shares, which the filing states includes 70,500 restricted stock units (RSUs). The sale was executed under a Rule 10b5-1 instruction letter adopted May 31, 2023, to satisfy the reporting person's tax withholding obligations upon RSU vesting after July 15, 2023. The Form 4 was signed by an attorney-in-fact on behalf of Ms. Horn on 09/18/2025.
Insider sale to cover taxes: This Form 4 shows Jeff Cislini, General Counsel of Revolution Medicines, executed a sale of 1,869 shares of common stock on 09/16/2025 at $45.8249 per share under a Rule 10b5-1 plan adopted May 31, 2023 to satisfy tax withholding for vested restricted stock units (RSUs). After the transaction he beneficially owns 52,224 shares, which includes 43,910 RSUs. The filing was signed by an attorney-in-fact on 09/18/2025. The disclosure is a routine insider tax-withholding sale rather than a discretionary trade.
Revolution Medicines insider sale to cover tax withholding following RSU vesting. Chief Financial Officer Jack Anders reported a sale of 2,320 shares of Revolution Medicines common stock on 09/16/2025 at an average price of $45.8249 per share, executed under a pre-existing Rule 10b5-1 instruction adopted May 31, 2023 to satisfy tax withholding obligations tied to RSU vesting after July 15, 2023. After the transaction Mr. Anders beneficially owned 110,994 shares, which the filing notes includes 48,275 restricted stock units. The Form 4 is signed and dated 09/18/2025.
FAQ
What is the current stock price of Revolution Medicines (RVMD)?
What is the market cap of Revolution Medicines (RVMD)?
